Open Access

Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells

  • Authors:
    • Cong Wang
    • Liubin Guo
    • Saiqi Wang
    • Junwei Wang
    • Yongmei Li
    • Yinhui Dou
    • Ran Wang
    • Hongge Shi
    • Yu Ke
    • Hongmin Liu
  • View Affiliations

  • Published online on: January 24, 2017     https://doi.org/10.3892/ijmm.2017.2867
  • Pages: 645-653
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemoresistance to anticancer drugs is a major obstacle in the efforts to develop a successful treatment strategy for esophageal squamous carcinoma (ESCC). Thus, the exploration of new drugs and treatment strategies for combating resistance are of utmost importance. In this study, we investigated the antitumor drug resistance activity of Jesridonin, a new ent-kaurene diterpenoid, and its possible mechanisms of action using the resistant cancer cell line, EC109/Taxol. MTT assay revealed that Jesridonin had similar IC50 values against EC109 paclitaxel-sensitive cells and drug-resistant EC109/Taxol cells in vitro. In mice, Jesridonin effectively prevented the growth of EC109/Taxol tumor xenografts without exerting any significant toxicity. In addition, Jesridonin significantly inhibited the proliferation of EC109/Taxol cells, induced apoptosis and arrested the cell cycle at the G2/M phase. Furthermore, western blot analysis revealed that Jesridonin upregulated the expression of p53, p53 upregulated modulator of apoptosis (PUMA), cleaved-caspase-9 and cleaved-caspase-3 in EC109/Taxol cells, and downregulated the expression of procaspase-3, procaspase-9 and Bcl-2 in the EC109/Taxol cells in a concentration-dependent manner. Overall, our results demonstrate that Jesridonin may have potential for use in the treatment of paclitaxel-resistant ESCC. The data of the present study may lead to the development of novel treatment strategies for paclitaxel-resistant tumors.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 39 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang C, Guo L, Wang S, Wang J, Li Y, Dou Y, Wang R, Shi H, Ke Y, Liu H, Liu H, et al: Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells. Int J Mol Med 39: 645-653, 2017
APA
Wang, C., Guo, L., Wang, S., Wang, J., Li, Y., Dou, Y. ... Liu, H. (2017). Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells. International Journal of Molecular Medicine, 39, 645-653. https://doi.org/10.3892/ijmm.2017.2867
MLA
Wang, C., Guo, L., Wang, S., Wang, J., Li, Y., Dou, Y., Wang, R., Shi, H., Ke, Y., Liu, H."Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells". International Journal of Molecular Medicine 39.3 (2017): 645-653.
Chicago
Wang, C., Guo, L., Wang, S., Wang, J., Li, Y., Dou, Y., Wang, R., Shi, H., Ke, Y., Liu, H."Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells". International Journal of Molecular Medicine 39, no. 3 (2017): 645-653. https://doi.org/10.3892/ijmm.2017.2867